+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CorMedix Inc (CRMD) - Product Pipeline Analysis, 2018 Update

  • PDF Icon

    Company Profile

  • 32 Pages
  • May 2018
  • GlobalData
  • CorMedix Inc
  • ID: 4542841
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company’s neutrolin is a catheter lock solution for the prevention of catheter related bloodstream infections. Its neutrolin is a novel formulation of taurolidine, citrate and heparin that provides preventative solution by decreasing the triple threat of infection. CorMedix is also developing therapeutic products for the prevention and treatment of inflammatory diseases. It markets its products through its distribution network. CorMedix is headquartered in Bedminster, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

  • The report analyzes all pipeline products in development for the company CorMedix Inc

  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

  • The report provides detailed description of products in development, technical specification and functions

  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

  • To formulate effective Research & Development strategies

  • Develop market-entry and market expansion strategies

  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • CorMedix Inc Company Overview

  • CorMedix Inc Company Snapshot

  • CorMedix Inc Pipeline Products and Ongoing Clinical Trials Overview

  • CorMedix Inc - Pipeline Analysis Overview

  • CorMedix Inc - Key Facts

  • CorMedix Inc - Major Products and Services

  • CorMedix Inc Pipeline Products by Development Stage

  • CorMedix Inc Ongoing Clinical Trials by Trial Status

  • CorMedix Inc Pipeline Products Overview

  • CRMD-006 - Scaffold

  • CRMD-006 - Scaffold Product Overview

  • Neutrolin

  • Neutrolin Product Overview

  • Neutrolin Clinical Trial

  • Taurolidine Surgical Mesh

  • Taurolidine Surgical Mesh Product Overview

  • Taurolidine Sutures

  • Taurolidine Sutures Product Overview

  • Taurolidine Wound Closures

  • Taurolidine Wound Closures Product Overview

  • Urine Labile Iron Test

  • Urine Labile Iron Test Product Overview

  • CorMedix Inc - Key Competitors

  • CorMedix Inc - Key Employees

  • CorMedix Inc - Locations And Subsidiaries

  • Head Office

  • Other Locations & Subsidiaries

  • Recent Developments

  • CorMedix Inc, Recent Developments

  • Feb 20, 2018: CorMedix Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin for Interim Efficacy Analysis

  • Dec 05, 2017: Cormedix Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases

  • Nov 29, 2017: CorMedix to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology

  • Sep 07, 2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris

  • Aug 17, 2017: CorMedix Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and Prevention of Potentially Life-Threatening Infections in Severe Burns

  • Aug 02, 2017: Cormedix Provides Update On Neutrolin Ongoing Phase 3 Clinical Trial Following Favorable FDA Correspondence

  • Apr 20, 2017: Cormedix Reports Update On Neutrolin Phase 3 LOCK-IT 100 Clinical Trial

  • Jun 13, 2016: Cormedix Announces Publication of Pharmacoeconomic Study that Highlights the Clinical and Economic Need for Products that can Prevent Catheter-Related Bloodstream Infections

  • May 23, 2016: Cormedix Presented Post-Market Clinical Utility Data from Neutrolin Usage Monitoring Program at 53RD Joint Congress of the European Renal Association - European Dialysis and Transplant Association

  • May 18, 2016: Cormedix Announces Publication of New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections at the Ispor 21st Annual International Meeting

  • Appendix

  • Methodology

  • About

  • Contact

  • Disclaimer

List of Tables
  • CorMedix Inc Pipeline Products and Ongoing Clinical Trials Overview

  • CorMedix Inc Pipeline Products by Equipment Type

  • CorMedix Inc Pipeline Products by Indication

  • CorMedix Inc Ongoing Clinical Trials by Trial Status

  • CorMedix Inc, Key Facts

  • CorMedix Inc, Major Products and Services

  • CorMedix Inc Number of Pipeline Products by Development Stage

  • CorMedix Inc Pipeline Products Summary by Development Stage

  • CorMedix Inc Ongoing Clinical Trials by Trial Status

  • CorMedix Inc Ongoing Clinical Trials Summary

  • CRMD-006 - Scaffold - Product Status

  • CRMD-006 - Scaffold - Product Description

  • Neutrolin - Product Status

  • Neutrolin - Product Description

  • Neutrolin - A Novel Taurolidine Containing Catheter Lock Solution (CLS) without Reported Antimicrobial Resistance, Reduces the Rates of Infection And Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study (NUMP)

  • Neutrolin - Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety and Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease

  • Taurolidine Surgical Mesh - Product Status

  • Taurolidine Surgical Mesh - Product Description

  • Taurolidine Sutures - Product Status

  • Taurolidine Sutures - Product Description

  • Taurolidine Wound Closures - Product Status

  • Taurolidine Wound Closures - Product Description

  • Urine Labile Iron Test - Product Status

  • Urine Labile Iron Test - Product Description

  • CorMedix Inc, Key Employees

  • CorMedix Inc, Subsidiaries

  • Glossary

List of Figures
  • CorMedix Inc Pipeline Products by Equipment Type

  • CorMedix Inc Pipeline Products by Development Stage

  • CorMedix Inc Ongoing Clinical Trials by Trial Status



Companies Mentioned

A selection of companies mentioned in this report includes:

  • GeneThera Inc
  • Galectin Therapeutics Inc
  • Cempra Inc
  • Argos Therapeutics Inc